A lesion-selective albumin-CTLA4Ig as a safe and effective treatment for collagen-induced arthritis

Background CTLA4Ig is a dimeric fusion protein of the extracellular domain of cytotoxic T-lymphocyte protein 4 (CTLA4) and an Fc (Ig) fragment of human IgG_1 that is approved for treating rheumatoid arthritis. However, CTLA4Ig may induce adverse effects. Developing a lesion-selective variant of CTLA4Ig may improve safety while maintaining the efficacy of the treatment. Methods We linked albumin to the N-terminus of CTLA4Ig (termed Alb-CTLA4Ig) via a substrate sequence of matrix metalloproteinase (MMP). The binding activities and the biological activities of Alb-CTLA4Ig before and after MMP digestion were analyzed by a cell-based ELISA and an in vitro Jurkat T cell activation assay. The efficacy and safety of Alb-CTLA4Ig in treating joint inflammation were tested in mouse collagen-induced arthritis. Results Alb-CTLA4Ig is stable and inactive under physiological conditions but can be fully activated by MMPs. The binding activity of nondigested Alb-CTLA4Ig was at least 10,000-fold weaker than that of MMP-digested Alb-CTLA4Ig. Nondigested Alb-CTLA4Ig was unable to inhibit Jurkat T cell activation, whereas MMP-digested Alb-CTLA4Ig was as potent as conventional CTLA4Ig in inhibiting the T cells. Alb-CTLA4Ig was converted to CTLA4Ig in the inflamed joints to treat mouse collagen-induced arthritis, showing similar efficacy to that of conventional CTLA4Ig. In contrast to conventional CTLA4Ig, Alb-CTLA4Ig did not inhibit the antimicrobial responses in the spleens of the treated mice. Conclusions Our study indicates that Alb-CTLA4Ig can be activated by MMPs to suppress tissue inflammation in situ. Thus, Alb-CTLA4Ig is a safe and effective treatment for collagen-induced arthritis in mice.

• Publication year

  2023

• Venue

  Inflammation and Regeneration

• Publication date

  2023-02-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s41232-023-00264-8PMID 36797799PMCID 9933273
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors

  2022cited by this paper
• Exploiting protease activation for therapy

  2022cited by this paper
• Dissecting the molecular control of immune cell accumulation in the inflamed joint

  2022cited by this paper
• A review on applications of abatacept in systemic rheumatic diseases.

  2021cited by this paper
• ADG153, an Anti-CD47 Monoclonal Antibody Prodrug, Has Strong In Vivo Anti-Tumor Activity, Minimal RBC-Related and Antigen Sink Liabilities, and Extended Half Life in Comparison with Benchmark Clinical Antibodies of the Same IgG Subclass

  2021cited by this paper
• Comparative efficacy and safety of biologic agents in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.

  2021cited by this paper
• Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy

  2021cited by this paper
• A Tale of Two Immune Cells in Rheumatoid Arthritis: The Crosstalk Between Macrophages and T Cells in the Synovium

  2021cited by this paper
• The Uniqueness of Albumin as a Carrier in Nanodrug Delivery.

  2021cited by this paper
• Restoring the Balance between Pro-Inflammatory and Anti-Inflammatory Cytokines in the Treatment of Rheumatoid Arthritis: New Insights from Animal Models

  2021cited by this paper
• Overproduced bone marrow neutrophils in collagen‐induced arthritis are primed for NETosis: An ignored pathological cell involving inflammatory arthritis

  2020cited by this paper
• Rheumatoid arthritis

  2020cited by this paper
• Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study

  2020cited by this paper
• Ab locks for improving the selectivity and safety of antibody drugs

  2020cited by this paper
• Rheumatoid arthritis

  2020cited by this paper
• Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy

  2019cited by this paper
• Development of an inflammatory tissue‐selective chimeric TNF receptor

  2019cited by this paper
• Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study.

  2019cited by this paper
• The past, present and future perspectives of matrix metalloproteinase inhibitors.

  2019cited by this paper
• Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study

  2019cited by this paper
• Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

  2019cited by this paper
• Post‐transplant lymphoproliferative disorders, Epstein‐Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

  2019cited by this paper
• Enriched Cd141+ DCs in the joint are transcriptionally distinct, activated, and contribute to joint pathogenesis.

  2018cited by this paper
• MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis.

  2018cited by this paper
• In Situ Activation of Pituitary-Infiltrating T Lymphocytes in Autoimmune Hypophysitis

  2017cited by this paper
• Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care

  2017cited by this paper
• Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains

  2017cited by this paper
• Metalloproteinases in Rheumatoid Arthritis: Potential Therapeutic Targets to Improve Current Therapies.

  2017cited by this paper
• Effects of CTLA4-Ig on human monocytes

  2017cited by this paper
• VpreB serves as an invariant surrogate antigen for selecting immunoglobulin antigen-binding sites

  2016cited by this paper
• Matrix metalloproteinase-9 (MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer.

  2016cited by this paper
• Synovial fluid proteome in rheumatoid arthritis

  2016cited by this paper
• Matrix Metalloproteinases in Inflammatory Bowel Disease: An Update

  2015cited by this paper
• Combinatorial proteomic analysis of intercellular signaling applied to the CD28 T-cell costimulatory receptor

  2015cited by this paper
• Matrix metalloproteinases as biomarkers of disease: updates and new insights

  2015cited by this paper
• Abatacept decreases disease activity in a absence of CD4+ T cells in a collagen-induced arthritis model

  2015cited by this paper
• The Efficacy of Abatacept in Reducing Synovial T Cell Activation by CD1c Myeloid Dendritic Cells Is Overruled by the Stimulatory Effects of T Cell–Activating Cytokines

  2015cited by this paper
• Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis.

  2013cited by this paper
• Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program

  2013cited by this paper
• Intra-articular CD1c-expressing myeloid dendritic cells from rheumatoid arthritis patients express a unique set of T cell-attracting chemokines and spontaneously induce Th1, Th17 and Th2 cell activity

  2013cited by this paper
• Indoleamine 2,3 dioxygenase and metabolic control of immune responses.

  2013cited by this paper
• Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

  2013cited by this paper
• Brief report: amelioration of collagen-induced arthritis in mice by lentivirus-mediated silencing of microRNA-223.

  2012cited by this paper
• Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases.

  2012cited by this paper
• In Vivo Positron Emission Tomography Imaging of Protease Activity by Generation of a Hydrophobic Product from a Noninhibitory Protease Substrate

  2011cited by this paper
• Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis

  2011cited by this paper
• The pathogenesis of rheumatoid arthritis.

  2011cited by this paper
• Cleavage of IgGs by proteases associated with invasive diseases

  2010cited by this paper
• Rigid-body Ligand Recognition Drives Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Receptor Triggering

  2010cited by this paper
• A multiparameter approach to monitor disease activity in collagen-induced arthritis

  2010cited by this paper
• Blocking Effect of an Immuno-Suppressive Agent, Cynarin, on CD28 of T-Cell Receptor

  2009cited by this paper
• Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase.

  2008cited by this paper
• The pathogenesis of rheumatoid arthritis.

  2007cited by this paper
• Collagen-induced arthritis

  2007cited by this paper
• Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

  2005cited by this paper
• CD1a and CD1c Activate Intrathyroidal T Cells during Graves’ Disease and Hashimoto’s Thyroiditis1

  2005cited by this paper
• Protein structure prediction and analysis using the Robetta server

  2004influential reference
• Publisher's Note

  2003cited by this paper
• CTLA-4–Ig regulates tryptophan catabolism in vivo

  2002cited by this paper
• Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin.

  2002cited by this paper
• T Cell Activation in Rheumatoid Synovium Is B Cell Dependent1

  2001cited by this paper
• Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis

  2000cited by this paper
• Structure of murine CTLA-4 and its role in modulating T cell responsiveness.

  2000cited by this paper
• Crystal structure of human serum albumin at 2.5 A resolution.

  1999cited by this paper
• CD28/B7 system of T cell costimulation.

  1996cited by this paper
• Prevention and amelioration of collagen‐induced arthritis by blockade of the CD28 co‐stimulatory pathway: requirement for both B7‐1 and B7‐2

  1996cited by this paper
• Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.

  1992cited by this paper
• CTLA-4 is a second receptor for the B cell activation antigen B7

  1991influential reference

• Advances in Subclinical and Clinical Trials and Immunosuppressive Therapies in Xenotransplantation

  2025cites this paper
• Predictive value of erythrocyte sedimentation rate, albumin and CRP for infection risk in elderly rheumatoid arthritis patients undergoing treatment.

  2025cites this paper
• Target Role of Monocytes as Key Cells of Innate Immunity in Rheumatoid Arthritis

  2024cites this paper
• The immunomodulatory of interleukin-33 in rheumatoid arthritis: A systematic review.

  2024cites this paper
• Advancements in rheumatoid arthritis therapy: a journey from conventional therapy to precision medicine via nanoparticles targeting immune cells.

  2024cites this paper
• Development of an Albumin-Masked mutPD-1Ig as a Tumor Lesion-Selective Immune Checkpoint Inhibitor

  2023cites this paper